Device Trial Radar · NCT00291525
Randomized On-X Anticoagulation Trial
Last checked: Nov 20, 2026Latest source record: Dec 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
977
Actual
Start
Jun 6, 2006
Primary completion
Aug 8, 2023
Study completion Dec 29, 2023
Sponsor
- Lead sponsor
- On-X Life Technologies, Inc.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Clinipace Worldwide; Acelis Connected Health; WCG IRB; Avania
- First posted
- Feb 14, 2006
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Various patient groups with the On-X Valve can be maintained safely on lower doses of blood thinner(Coumadin®) or on antiplatelet drugs (aspirin/Plavix®) only rather than the standard dose of Coumadin and aspirin presently recommended by ACC/AHA or ACCP professional societies.
Conditions
- Heart Valve Disease
Interventions
On-X valve using reduced anticoagulationDevice
Valve replacement with antiplatelet agents or lowered warfarin
On-X Valve with Standard warfarin TherapyDevice
Valve replacement with standard dosage warfarin
Primary outcomes
What the sponsor says the trial is designed to measure.
- ThromboembolismTime frame: 8 years
- Valve ThrombosisTime frame: 8 years
- Bleeding EventsTime frame: 8 years
Locations
49 sites in 2 countries. Site status is shown where the registry gives one.
Tucson Medical Center
Tucson, Arizona
Southern Arizona VA Medical Center
Tucson, Arizona
Loma Linda University
Loma Linda, California
46 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.